← Drug database

Ciambra (pemetrexed)

Generic
Region
🇪🇺 EU
Active substance
pemetrexed
Company
Menarini International Operations Luxembourg S.A.
Status
Withdrawn
Therapeutic area
Carcinoma, Non-Small-Cell Lung; Mesothelioma
CHMP opinion
Thu 24 Sep 2015
EU approval
Wed 02 Dec 2015
Designations
Generic
Application
EMEA/H/C/003788
ATC
L01BA04
Official record
www.ema.europa.eu

Indication

Malignant pleural mesothelioma Ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Ciambra is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Ciambra is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Ciambra

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.